Stocks On the Move: Fred's, Inc., Akebia Therapeutics Inc, and TESARO Inc

Discount retailer Fred's, Inc. (FRED), as well as biotech stocks Akebia Therapeutics Inc (AKBA) and TESARO Inc (TSRO) are among the stocks making big moves in today's trading

Dec 20, 2016 at 3:21 PM
facebook X logo linkedin


U.S. stocks are higher as telecom stocks rally. Among specific equities in focus today are discount retailer and pharmacy Fred's, Inc. (NASDAQ:FRED), as well as biotech stocks Akebia Therapeutics Inc (NASDAQ:AKBA) and TESARO Inc (NASDAQ:TSRO). Here's a quick look at what's moving FRED, AKBA, and TSRO.

  • FRED is up a whopping 92.3% at $21.44, and is among the best Nasdaq performers today, after Rite Aid Corporation (NYSE:RAD) announced it would be selling 865 stores to Fred's, Inc. for $950 millionto satisfy antitrust requirements regarding its merger with Walgreens Boots Alliance Inc (NASDAQ:WBA). Earlier, FRED touched a 12-year high of $21.77, and is now up 135% so far in the fourth quarter. Short sellers may be sweating, with FRED's short interest accounting for 9.8% of its float, which would take 12.4 days of trading to cover, at FRED's average daily volume.

  • AKBA is up 25.8% at $10.50, and is also among the top performers on the Nasdaq, after the biotech signed a deal with Japanese firm Otsuka Holdings Co Ltd for the development and marketing of an experimental anemia drug. AKBA will receive $265 million up front, with potential to receive more than $1 billion. Although AKBA still sits down 21% so far in 2016, today's move puts the shares above the $9.50-$10 area that has served as resistance since an early January bear gap. Quite a few short sellers may be finding themselves under water, given AKBA's shorted shares account for 12.1% of the stock's float, which would take nearly three weeks of trading to cover, at AKBA's average daily volume.
  • TSRO is 5.2% higher at $133.84, after the biotech's ovarian cancer treatment, niraparib, was granted a priority review designation by the U.S. Food and Drug Administration (FDA), just a day after sector peer Clovis Oncology Inc (NASDAQ:CLVS) was granted accelerated approval for its ovarian cancer drug. According to one Wedbush analyst, TESARO Inc's niraparib would be the "likely winner" in a head-to-head showdown between the two drugs, with the brokerage firm reiterating an "outperform" endorsement for TSRO. TSRO shares have been on a trek higher since a late-June bear gap, more than tripling in the past six months. Still, TSRO's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 1.17 sits in the top quartile of its annual range, pointing to a healthier-than-usual appetite for long puts over calls of late.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI